October 15, 2020

EMA launches public consultation on the draft Guideline concerning registry-based studies

Last September, the EMA published its draft Guideline on registry-based studies (“Guideline”). This draft Guideline is currently open for public consultation: stakeholders may post comments until December 31, 2020.

A registry-based study is an investigation of a research question using data from a new or existing patient registry for patient recruitment and data collection. Patient registries are data collection systems for data on a group of people with a particular disease or condition; a registry is established for a specific purpose and used to conduct a registry-based study. Registries contain a lot of information on diseases, patients, standards of care, use of medicines, devices, and results of care and have already been the subject of initiatives carried out by the EMA since September 2015 (with regard to the initiative for patient registries launched in November 2018, please also refer to our article “Registri di malattia dei pazienti: potenzialità di utilizzo a fini regolatori”).

A registry-based study may be a clinical study or a non-interventional study. Studies based on patient registries provide real evidence to complement the results obtained from clinical trials and pre-clinical studies and to improve knowledge about the risks and benefits associated with the daily use of medicines.

The Guideline provides regulatory requirements and recommendations on key methodological aspects for the use of patient registries by marketing authorization applicants and holders in order to carry out studies, including the following:

  • planning a registry-based study requires identifying one suitable registry or multiple suitable registries and obtaining agreement to participate from each registry, as well as from each individual center if no central registry coordination exists, potentially selecting a third party to be involved in the study and set up a database, and establishing a data extraction process and quality control practices (par. 3.3 of the Guideline);
  • the study protocol should describe how the registry infrastructure and population will be used to address the scientific question at stake, how the study will be conducted, and how the validity of the results will be ensured (par. 3.4 of the Guideline).

The final version of Guideline will reflect stakeholders’ comments and will be published in 2021.

< Back to blog
Welcome to the Portolano Cavallo Life Sciences blog focusing on legal development and key legal issues affecting the life sciences and healthcare industry.
Read more
Our highly-ranked team of professionals will provide news, insights and multidisciplinary commentary on the hottest and most recent regulatory, transactional and contentious aspects of the pharmaceutical, bio-tech, med-tech, food supplement and healthcare world with an eye on its digital transformation and technological developments.

This blog will be a place for focusing on digital health, telemedicine and artificial intelligence, as well as more traditional topics: from the protection of intellectual properties to performance of clinical trials, from the market access to advertising and competition issues, from internal and criminal investigations to M&A and venture capital transactions.

October 6, 2023
CBD products: the Administrative Court suspended until October 24 the recent Decree of the Italian Ministry of Health listing cannabidiol for oral use among narcotic drugs, due to the lack o...
October 4, 2023
The Guidelines for regulating contractual relations between universities and research institutes and private sponsors were adopted by the relevant Italian Ministries following the amendment ...
September 21, 2023
CBS products: from September 20th, compositions for oral administration of cannabidiol obtained from Cannabis sativa extracts shall be considered as narcotic drugs in Italy, as they have bee...
July 27, 2023
Payback on medical devices: Italian government announces extension of payment deadline to October 30, 2023
July 21, 2023
On July 21, 2023, the Italian Ministry of Health published new guidelines on health advertising of self-medication drugs (OTC) and non-prescription drugs (SOP), including advertising on new ...
Search by...
Follow us on
Follow us on